EGFR and Hypertension: Moreover, atezolizumab plus bevacizumab plus chemotherapy showed significant improvements in PFS and OS in EGFR TKI-resistant patients; however, the incidence of adverse reactions was higher, especially for antiangiogenesis-related AEs such as hypertension and proteinuria [31, 32].